The case for therapeutic vaccines

Melanoma Research

Volumn 6, Issue 1, 1996, Pages 5-10

  Dalgleish, A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

CANCER IMMUNOTHERAPY; CLINICAL TRIAL; GENE THERAPY; HUMAN; MELANOMA; PRIORITY JOURNAL; REVIEW;

CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY, ACTIVE; MELANOMA;

EID: 0030022217     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199602000-00002     Document Type: Review

References (45)

1. Dalgleish AG, Sikora K. Melanoma. In Waxman J, ed. Interleukin-2. Oxford: Blackwell Science, 1992: 132-144.
2. Morton DL, Ravindranath MH. Active specific immunotherapy with vaccines. In Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer Medicine 3rd ed, vol 1, 1993: 913-926.
3. Morton DL, Foshag LJ, Hoon DSB, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 465-482.
4. Morton DL, Hoon DSB, Nizze J, et al. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann N Y Acad Sci 1993; 690: 120-134
5. Mitchell MS. Active specific immunotherapy of cancer: therapeutic vaccines ('theracines') for the treatment of disseminated malignancies. In Mitchell MS, ed. Biological Approaches to Cancer Treatment: Biomodulation. New York: McGraw-Hill, 1992: 326-351.
6. Mitchell MS, Harel W, Kan-Mitchell J, et al. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results and possible mechanisms of action. Ann N Y Acad Sci 1993; 690: 153-166.
7. Bystryn J-C, Orzta R, Harris MN, et al. Immunogenicity of a polyvalent melanoma antigen vaccine in humans. Cancer 1988; 61: 1065-1072.
8. Bystryn JC, Orzta M, Henn A et al. Relationship between immune response to melanoma vaccine and clinical outcome in stage II malignant melanoma. Cancer 1992; 69: 1157-1164.
9. Portoukalian J, Carrel S, Dore JF, et al. Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associated gangliosides. Int J Cancer 1991; 49: 893-899.
10. Wallack MK, Meyer M, Bourgoin A, et al. A preliminary trial of vaccinia oncolysates in the treatment of recurrent melanoma with serologic responses to the treatment. J Biol Res Mod 1983; 2: 586-592.
11. Wallack MC, Bash JA, Leftheriotis E, et al. Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. Arch Surg 1987; 122: 1460-1463.
12. Hersey P, Edwards A, Coates A, et al. Evidence that treatment with vaccinia cell lysates may improve survival of patients with Stage II melanoma. Cancer Immunol Immunotherapy 1987; 25: 257-265.
13. Hersey P. Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. World J Surg 1992, 16: 251-260.
14. Doré JF, Portoukalian J, Berthier-Vergnes O, et al. Responses de malades atteints de melanome à l'immunisation par onoclysats de melanomes au virus de la vaccine. Bull Cancer 1990; 77: 881-891.
15. Livingston PO, Albino AP, Chung TJ, et al. Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer 1985; 55: 713-720.
16. Livingston PO, Ritter O, Srivastava P, et al. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989; 49: 7045-7050.
17. 3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res 1994; 54: 197-203.
18. Berd D, Maguire HC, McCue P, et al. Treatment of metastatic melanoma with an autologous tumour cell vaccine. J Clin Oncol 1990; 8: 1858-1867.
19. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumour regression in association with INF-gamma production. J Immunol 1994; 153: 1697-1706.
20. Brunda MJ, Luistro L, Warrier RR, et al. Anti-tumour and antimetastatic activity of Interleukin 12 against murine tumours. J Exp Med 1993; 178: 1223-1230.
21. Van Der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647.
22. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognised by the majority of HLA-A2 restricted tumour infiltrating lymphocytes. J Exp Med 1994; 180: 347-352.
23. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognised by autologous T-cells infiltrating into tumour. Proc Natl Acad Sci USA 1994; 91: 3515-3519.
24. Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264: 716-719.
25. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognised by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178: 489-495.
26. Wolfel T, Haver M, Schreider J, et al. A p16 INF4a-insensitive CDK4 Mutant targeted by CTLs in a human melanoma. Science 1995; 269: 1281-1283.
27. Dalgleish AG. Cancer vaccines. Eur J Cancer 1994; 30A: 1029-1035.
28. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumour cells. Hum Gene Ther 1994; 4: 153-164.
29. Hui K, Grosveld F, Festenstein H. Rejection of transplantable AKR leukaemic cells following MHC DNA-mediated cell transformation. Nature 1984; 311: 750-752.
30. Mandelboim O, Feldman M, Eisenbach L. H-2K double transfectants of tumour cells as antimetastatic cellular vaccines in heterozygous recipients. J Immunol 1992; 148: 3666-3673.
31. Fearon ER, Pardoll DM, Itay T, et al. IL-2 production by tumour cells bypasses T helper function in the generation of anti-tumour response. Cell 1990; 60: 3539-3543.
32. Gansbacher B, Zier K, Daniels B, et al. Retroviral vector-mediated gamma-interferon gene transfer into tumour cells generates potential and long lasting anti-tumour immunity. Cancer Res 1990; 50: 7820-7825.
33. Tepper R, Pattengale P, Leder P. Murine interleukin-4 displays potent anti-tumour activity in vivo. Cell 1989; 57: 503-512.
34. Porgador A, Tzehoval E, Katz A, et al. IL-6 gene transfection into Lewis lung carcinoma tumour cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992; 52: 3679-3686.
35. Asher AL, Mule JJ, Kasid A, et al. Murine tumour cells transduced with the gene for tumour necrosis factor-alpha. J Immunol 1991; 146: 3227-3234.
36. Hock H, Dorsch M, Diamantstein T, et al. IL-7 induces CD4+ T cell-dependent tumour rejection. J Exp Med 1991; 174: 1291-1298.
37. Colombo MP, Ferrari G, Stoppacciaro A, et al. Granulocyte colony-stimulating factor gene suppresses tumourgenicity of a murine adenocarcinoma in vivo. J Exp Med 1991; 173: 889-897.
38. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumour cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumour immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
39. Townsend SE, Allison JP. Tumour rejection after direct co-stimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993; 259: 368-370.
40. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumour immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-1102.
41. Srivastava PK, Udono H. Blachere NE, et al. Heat shock protein transfer peptides during antigen processing and CTL priming. Immunogenetics 1994; 39: 93-98.
42. Arnold D, Faath S, Rammensee H-G, et al. Cross-priming of minor histocompatibility antigen-specific cytotoxic T-cells upon immunization with the heat shock protein gp96. J Exp Med 1995; 182: 885-889.
43. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein chaperoned peptides. Science 1995; 269: 1585-1588.
44. Graham RA, Taylor-Papadimitriou J. Immune response to mucinsin. In: Dalgleish AG, Browning M, eds. Tumour Immunology. Cambridge: Cambridge University Press, 1995.
45. Vile R, Hart I. Use of tissue-specific expression of the Herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 1993; 53: 3860-3864.